Case presentation: A 71-year-old woman presented with extreme low back pain.
Introduction
Osteolytic disease is the most common complication of multiple myeloma (MM) leading to devastating skeletal-related events (SREs), such as pathological fractures, need for radiation or surgery and spinal cord compression [1] . A challenge for the physicians is the definition of myeloma-related bone disease in the absence of lytic lesions on the conventional radiography or the definition of a myeloma-related fracture in a post-menopausal woman, as in our case. The IMWG has suggested that patients with normal skeletal survey using conventional X-rays be evaluated with whole body MRI for the presence of focal lesions [2] . MRI can also differentiate the myeloma-related fracture from a benign osteoporotic-type fracture in the vast majority of cases [3] . In our case the diffuse pattern of infiltration in the fractured vertebra is highly suggestive of a myeloma-related fracture that needs anti-myeloma treatment and bone targeted agents. Bisphosphonates are the cornerstone for the For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 3 management of myeloma-related bone disease [1, 3] . Intravenous pamidronate and zoledronic acid and oral clodronate are the only drugs that have been licensed in different countries for the treatment of myeloma bone disease [1, 3] . The aim of this review is to provide practical recommendations for the use of bisphosphonates in MM based on the published current evidence.
Methodology
We reviewed all published randomized clinical studies, clinical guidelines and systematic reviews, meta-analyses, observational studies and case reports on the use of bisphosphonates in MM. Our research was performed through PubMed and ISI, until the 30 th of September 2012. We used the Grading of Recommendations Assessment Development and Evaluation (GRADE) system for the development of grades of recommendations (Table 1) .
When Should Treatment with Bisphosphonates Be Started?
During the last two decades, several randomized, placebo-controlled, trials have shown that oral clodronate, intravenous pamidronate and intravenous zoledronic acid effectively reduce bone pain, the incidence of SREs and time to first and subsequent SREs in patients with myeloma-related bone disease assessed by conventional radiography [4] [5] [6] . There are only 3 large randomized studies comparing two different bisphosphonates or two different dosages of the same bisphosphonate. In the first, which was performed in the conventional chemotherapy era, zoledronic acid was found as effective as pamidronate in reducing pain, incidence of SREs and delaying the time to first SRE [7] . In the second study, the every month) that were administered to 504 patients for more than three years. The authors showed that 30 mg of pamidronate produced comparable time to SRE and similar SRE-free survival time as 90 mg [8] . However, the study was powered to show quality of life differences only and not differences on SREs. Finally, the third study, which was conducted by the MRC (MRC-IX myeloma study), compared intravenous zoledronic acid (4 mg, every 3-4 weeks) with oral clodronate (1600 mg/daily) in approximately 2000 patients who received as an anti-myeloma therapy either conventional chemotherapy or thalidomide-based regimens [9] . The study included symptomatic myeloma patients who had bone disease by conventional skeletal radiography but also patients without bone lesions on the skeletal survey.
The authors found that zoledronic acid reduced the SRE risk by 26% compared to clodronate, regardless of the anti-myeloma treatment given to the patients.
Interestingly, this SRE reduction by zoledronic acid was evident in both patients with and without bone disease at diagnosis [10] . However, a recent meta-analysis by the Cochrane database was not able to confirm superiority of any one bisphosphonate over another (zoledronic acid versus pamidronate or clodronate) [11] . According to this latter analysis, bisphosphonates have to be administered in 6 to 15 myeloma patients in order to prevent a SRE in one of them [11] .
In patients with asymptomatic myeloma, no bisphosphonate has shown prolongation of time to progression to symptomatic disease [12, 13] .
Based on the available data we suggest that all patients with myeloma-related bone disease at diagnosis should to be treated with either zoledronic acid or pamidronate, intravenously, in addition to anti-myeloma therapy (GRADE 1A). 
Is There Any Anti-Myeloma Effect of Bisphosphonates?
Placebo-controlled, phase III, randomized studies in the conventional chemotherapy era showed that subsets of myeloma patients receiving bisphosphonates had a survival advantage. Patients with vertebral fractures had a superior survival with clodronate over placebo [4] , while patients who received second line anti-myeloma therapy and pamidronate had a borderline survival advantage against placebo [5] .
The recent MRC-IX study showed that zoledronic acid prolonged the median overall survival of the patients by 5.5 months over clodronate [9] . This was mainly due to the beneficial effect of zoledronic acid in patients who had bone disease at baseline.
Patients presenting with bone disease who received zoledronic acid had a survival advantage of 10 months, while all other patients had similar survival with those who received clodronate [14] . This result was independent of the anti-myeloma treatment that was administered to the patients. The recent Cochrane meta-analysis confirmed 
What Is the Appropriate Duration of Bisphosphonate Therapy?
In all randomized, placebo-controlled trials, the bisphosphonates were given for a maximum period of two years. Therefore, the recommended period of bisphosphonate administration was two years by all major associations and organizations, including ASCO and EMN. In the recent MRC-IX trial, the bisphosphonates were given until disease progression. The subset of patients who received zoledronic acid for more than 2 years continued to experience a reduction 
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We suggest that zoledronic acid should be given beyond two years only in patients with active myeloma (GRADE 1B). It is unclear if patients who achieve a CR will continue to have benefits from zoledronic acid administration. Since there are no data supporting the continuous use of pamidronate, pamidronate should be given initially for two years and then at the physician's discretion for patients with active disease (GRADE 2C).
How Can Bisphosphonates Be Used in Patients with Renal Impairment?
Renal impairment is another common complication of MM [15] . Both zoledronic acid and pamidronate can cause acute tubular damage and deterioration in renal function. In the MRC-IX study, 5% of patients in the autologous transplantation arm and 7% in the non-autologous transplantation arm who received zoledronic acid developed acute renal failure [9] . According to the SPC of the drug, zoledronic acid should be given at lower doses when there is renal impairment [ Table 2 ]. In the study comparing zoledronic acid with pamidronate, 10.7% of patients in the zoledronic acid group and 9.3% of patients in the pamidronate group had increased serum creatinine, while after 2 years of administration grade 3-4 serum creatinine increases occurred in 0.4% of patients in the zoledronic acid group and in 1.9% of patients in the pamidronate group [7] . Pamidronate's pharmacokinetics is characterized by a 2-3 hours distribution phase followed by rapid elimination of the drug in the urine. The elimination of pamidronate is slower in patients with a creatinine clearance (CrCl) <30 ml/min compared to patients with CrCl >90 ml/min [16] . A pharmacokinetic study with oral clodronate in patients with renal impairment but not with MM showed that clodronate can be given even in patients with ClCr <12 ml/minute at 50% of the normal dose [17] . 
Optimal Management of Bisphosphonates Side-effects
Side effects of bisphosphonates mainly include acute phase reactions, hypocalcemia, hypophosphatemia, gastrointestinal events after oral administration and inflammatory reactions at the injection site [4] [5] [6] [7] [8] [9] . Osteonecrosis of the jaw (ONJ)
is an important but rare complication of bisphosphonates, more often observed with zoledronic acid and prolonged administration of bisphosphonates [18] . The use of preventive dental measures has reduced the incidence of ONJ [19] . Regarding precautions before dental extraction in patients who received bisphosphonates, the most recent ADA recommendations do not suggest suspension of bisphosphonates in these cases, since there is not data that it helps and bisphosphonates persist for years in bone [20] .
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For the management of these side effects we suggest that calcium and vitamin D3 supplementation should be used in all patients to maintain calcium homeostasis (GRADE 1A). Caution is required for patients with renal insufficiency. Patients should receive a thorough dental examination and all dental problems treated before the initiation of bisphosphonates (GRADE 2C).
If ONJ develops, the bisphosphonates should be stopped; they can be readministered according to physician opinion (GRADE 2C).
Conclusion
Bisphosphonates should be considered in all patients with myeloma-related bone disease. Intravenous zoledronic acid or pamidronate are the recommended bisphosphonates. Zoledronic acid should be given continuously in patients with active disease, while pamidronate should be given for two years and then at the 
